Biogen (NASDAQ:BIIB) Given New $187.00 Price Target at Wedbush

Biogen (NASDAQ:BIIB) had its price target hoisted by equities research analysts at Wedbush from $178.00 to $187.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has a “neutral” rating on the biotechnology company’s stock. Wedbush’s price objective indicates a potential downside of 7.05% from the stock’s previous close.

Several other equities analysts have also recently weighed in on BIIB. Jefferies Financial Group raised their price target on Biogen from $190.00 to $210.00 and gave the company a “buy” rating in a report on Friday, November 28th. UBS Group initiated coverage on shares of Biogen in a report on Tuesday, January 6th. They issued a “neutral” rating and a $185.00 target price for the company. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Biogen in a research note on Monday. Tudor Pickering set a $157.00 price objective on shares of Biogen in a research note on Monday, November 3rd. Finally, Wells Fargo & Company set a $200.00 target price on shares of Biogen in a research report on Sunday. Twelve investment analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $202.38.

Biogen Price Performance

Shares of NASDAQ:BIIB opened at $201.18 on Monday. The firm has a market cap of $29.51 billion, a price-to-earnings ratio of 22.84, a P/E/G ratio of 1.70 and a beta of 0.16. The firm has a fifty day moving average price of $176.94 and a 200 day moving average price of $157.05. Biogen has a fifty-two week low of $110.04 and a fifty-two week high of $202.41. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, topping the consensus estimate of $1.61 by $0.38. The business had revenue of $2.28 billion for the quarter, compared to analysts’ expectations of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The business’s quarterly revenue was down 7.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, sell-side analysts expect that Biogen will post 15.83 earnings per share for the current fiscal year.

Insider Activity at Biogen

In related news, insider Priya Singhal sold 748 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $179.30, for a total transaction of $134,116.40. Following the transaction, the insider directly owned 6,271 shares of the company’s stock, valued at $1,124,390.30. This represents a 10.66% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 0.18% of the company’s stock.

Hedge Funds Weigh In On Biogen

Hedge funds have recently modified their holdings of the stock. Privium Fund Management B.V. purchased a new position in Biogen in the second quarter valued at $2,666,000. Nordea Investment Management AB raised its position in Biogen by 5.7% in the 2nd quarter. Nordea Investment Management AB now owns 125,935 shares of the biotechnology company’s stock valued at $15,810,000 after purchasing an additional 6,811 shares in the last quarter. Pitcairn Co. purchased a new position in shares of Biogen in the 2nd quarter valued at about $936,000. Convergence Investment Partners LLC acquired a new position in shares of Biogen during the third quarter worth about $1,342,000. Finally, Fluent Financial LLC purchased a new stake in shares of Biogen during the third quarter worth approximately $3,578,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Multiple firms raised price targets and reiterated buy views — HC Wainwright lifted its PT to $228 and Stifel moved to $214 (both buy). These upgrades support upside expectations for the stock.
• Positive Sentiment: Q4 results beat expectations: EPS $1.99 vs. $1.61 est., revenue topped estimates and management issued strong FY2026 EPS guidance (15.25–16.25), which underpins the rally. Biogen shares rise as Q4 earnings beat expectations, 2026 profit outlook strong
• Positive Sentiment: Commercial momentum for Leqembi is a key catalyst — sales jumped and market optimism rose after reports China fast‑tracked at‑home use of Leqembi, which could open a major market. Biogen stock to pop again? China fast-tracks at-home Alzheimer’s drug Leqembi
• Positive Sentiment: Shares recently hit a 52‑week high on the earnings/Leqembi news, reinforcing momentum and investor interest. Biogen Hits 52-Week High, Alzheimer’s Drug Sales Jump
• Neutral Sentiment: Analyst nuance: TD Cowen and others maintain bullish views citing undervaluation and growing Leqembi cash flows, but nuance remains around sustainability. Biogen: Undervalued Cash Flows and Growing Leqembi Franchise Support Raised Price Target and Buy Rating
• Neutral Sentiment: Deeper analysis: some coverage frames FY25 EPS as “stable” but notes pressure from the MS franchise — a balanced read for investors weighing sustainability. Biogen FY25 Earnings: Stable EPS, Amid Pressure From The Multiple Sclerosis Franchise
• Negative Sentiment: MS franchise weakness: core MS sales declined, which weighed on top‑line growth and is flagged as a recurring headwind by some outlets. Biogen Revenue Down as Multiple Sclerosis Sales Slide
• Negative Sentiment: Some major sell‑side analysts (Morgan Stanley, UBS) remain at Hold with lower PTs (~$185–$190), citing limited near‑term growth and pipeline/execution risk — these views cap upside for more cautious investors. Biogen: Limited Near-Term Growth and Execution Risks Justify Neutral Hold Rating Biogen: Solid Near-Term Execution but High-Risk Pipeline Keeps Rating at Hold

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.